Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 203 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sweat Gland Diseases Clear all
Completed Not applicable Interventional

Caspofungin Acetate in Treating Children With Fever and Neutropenia

NCT00020527
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
Interventions
caspofungin acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 22, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Results available

Hidradenitis Suppurativa Study of Izokibep

NCT05905783
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Placebo, Izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
infliximab, Placebo Comparator
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2008 · Synced Jul 22, 2026, 8:15 PM EDT
Not listed Phase 4 Interventional

A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions

NCT05477225
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
NovoSorb® BTM, Human Cadaveric Allograft
Device
Lead sponsor
Joseph M. Still Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 22, 2026, 8:15 PM EDT
Withdrawn Phase 2 Interventional

Gentian Violet Treatment for Hidradenitis Suppurativa

NCT04388163
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Gentian Violet
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

NCT00918255
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Jul 22, 2026, 8:15 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 22, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT01838499
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
MEDI8968, Saline
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis

NCT01713959
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Ulthera System treatment, Sham treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Hidradenitis Suppurativa Phase 2b Study of Izokibep

NCT05355805
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Encino, California • Fountain Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Completed No phase listed Observational

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

NCT04804566
View directory record Official record
Conditions
Fabry Disease
Interventions
This is a non-interventional study
Other
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 22, 2026, 8:15 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06046729
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Eltrekibart, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating

NCT00509886
View directory record Official record
Conditions
Hyperhidrosis, Excess Sweating
Interventions
Drysol, Drioff
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

NCT02781818
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Anakinra as a Treatment for Hydradenitis Suppurativa

NCT01516749
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
anakinra
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

NCT02016885
View directory record Official record
Conditions
Hyperhidrosis
Interventions
glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%, glycopyrrolate, 4.0%, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Encinitas, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jul 22, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

NCT04414514
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib 1.5% Cream
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT04762277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab - solution for infusion, Placebo matching spesolimab - solution for infusion, Spesolimab- solution for injection, Placebo matching to spesolimab- solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients

NCT05470322
View directory record Official record
Conditions
Hidradenitis Suppurativa, Scarring
Interventions
Er: YAG laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
BFB759, Placebo for BFB759
Biological · Other
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Encino, California • Santa Monica, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

NCT02673619
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Umeclidinium, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
Omaha, Nebraska • Raleigh, North Carolina • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Jul 22, 2026, 8:15 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT06241573
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 8:15 PM EDT